Novabay Pharmaceuticals Inc [NBY] stock is trading at $13.45, down -29.80%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NBY shares have gain 99.26% over the last week, with a monthly amount glided 455.79%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Novabay Pharmaceuticals Inc [AMEX: NBY] stock has seen the most recent analyst activity on September 18, 2019, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $1.10. Previously, H.C. Wainwright reaffirmed its Buy rating on July 06, 2018, and kept the price target unchanged to $4. On November 15, 2017, Laidlaw reiterated its Buy rating and revised its price target to $8 on the stock. ROTH Capital started tracking the stock assigning a Buy rating and suggested a price target of $5.50 on June 05, 2017. Laidlaw initiated its recommendation with a Buy and recommended $10 as its price target on March 27, 2017. Rodman & Renshaw started tracking with a Buy rating for this stock on February 06, 2017, and assigned it a price target of $6. In a note dated March 07, 2016, Maxim Group downgraded a Hold rating on this stock.
Novabay Pharmaceuticals Inc [NBY] stock has fluctuated between $0.30 and $19.95 over the past year. Novabay Pharmaceuticals Inc [AMEX: NBY] shares were valued at $13.45 at the most recent close of the market.
Analyzing the NBY fundamentals
Novabay Pharmaceuticals Inc [AMEX:NBY] reported sales of 2.83M for the trailing twelve months, which represents a drop of -78.66%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -2.73%, Pretax Profit Margin comes in at -2.81%, and Net Profit Margin reading is 1.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.93, Equity is 1.09 and Total Capital is -3.79. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.59.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Novabay Pharmaceuticals Inc’s Current Ratio is 1.98. As well, the Quick Ratio is 1.98, while the Cash Ratio is 1.59. Considering the valuation of this stock, the price to sales ratio is 598.89.
Transactions by insiders
Recent insider trading involved POPLAR POINT CAPITAL PARTNERS, 10% Owner, that happened on Apr 03 ’25 when 22976.0 shares were purchased. 10% Owner, POPLAR POINT CAPITAL PARTNERS completed a deal on Apr 04 ’25 to buy 4538.0 shares. Meanwhile, 10% Owner POPLAR POINT CAPITAL PARTNERS bought 917.0 shares on Apr 02 ’25.
